Coronary artery disease (CAD), the most common cardiac disease, is caused by atherosclerosis in the coronary arteries, a condition which causes a decrease in the blood supply to the heart muscle. CAD may cause an impairment of the cardiac muscle function that significantly affects the left ventricular systolic function that performs as the main pump of the heart. Accurate evaluation of the LV function and other parts of the heart is crucial for correct patient diagnosis, treatment decisions and prognosis assessment.

.

Ultrasound imaging of the heart, or Echocardiography, is the most widely used imaging technique for evaluation of cardiac heart function. Today, approximately 15 million echo procedures are carried out worldwide each year.

.

Over the past few years, echocardiography systems have begun to offer better and faster imaging capabilities, coupled with measurement tools intended to assist with evaluation of heart function. However, these tools are manual or semi-automated, and are therefore slow, cumbersome to use and error-prone.

.

For example, the evaluation of LV function is done by subjective “eyeballing” (just by looking) of the LV, or by manually tracing the LV borders on manually-selected frames. Both techniques require the evaluator to draw on vast echo experience in order to achieve an accurate evaluation.

.

Manual tracing is both insufficiently accurate and time consuming (taking 15-30 minutes to perform). Even the semi-automatic measurements now provided on high-end machines have not proven to be sufficiently reliable. Using the tools currently available are limited in function evaluation. Some of the other parameters such as movements of ventricular wall segments (17 singular areas), can only be perform on most machines through “eyeball”-based evaluation.

.

In contrast, DiACardio’s technology enables a fully automatic dynamic analysis of the heart in action, including full automation of both tracing and analysis processes - performed in several second via a single click of the mouse - across the complete heart cycle. This is a revolutionary improvement compared with the conventional evaluation method, which use manually-selected still images as the basis for calculation.

.

The ease and speed of DiACardio’s tools also make it practical to carry out short-cycle, repeatable measurements of patients associated with the risk of the cardiotoxicity effect that may be caused by chemotherapy.

.

DiAcardio's tools are able to analyze patient data online within the echo unit and/or offline on the PACS's DICOM video file, taking into account the dynamic nature of the heart.

.

DiAcardio technologies are protected by patents (currently at the national phase).